Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

Nature Structural and Molecular Biology

Volumn 22, Issue 12, 2015, Pages 953-958

  Scapin, Giovanna ^a   Yang, Xiaoyu ^a   Prosise, Winifred W ^a   McCoy, Mark ^a   Reichert, Paul ^a   Johnston, Jennifer M ^a   Kashi, Ramesh S ^a   Strickland, Corey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; FC RECEPTOR; GLYCAN; HYDROGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; OXYGEN; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ARTICLE; DEGLYCOSYLATION; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; GLYCOSYLATION; HINGE REGION; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MUTATION; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; CHEMISTRY; HUMAN; IMMUNOLOGY; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN G; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84949533006     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.3129     Document Type: Article

References (40)

1. Mellman I., Coukos G., & Dranoff G. Cancer immunotherapy comes of age. Nature. 480, 480-489 (2011
2. Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat. Rev. Drug Discov. 12, 489-492 (2013
3. Aalberse R.C., & Schuurman J. IgG4 breaking the rules. Immunology. 105, 9-19 (2002
4. van der Neut Kolfschoten M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 317, 1554-1557 (2007
5. Jefferis R., & Lund J. Interaction sites on human IgG-Fc for Fc?R: current models. Immunol. Lett. 82, 57-65 (2002
6. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159-166 (2012
7. Kratzin H.D., et al. The primary structure of crystallizable monoclonal immunoglobulin IgG1 Kol. II. Amino acid sequence of the L-chain, gamma-Type, subgroup I. Biol. Chem. Hoppe Seyler. 370, 263-272 (1989
8. Guddat L.W., Herron J.N., & Edmundson A.B. Three-dimensional structure of a human immunoglobulin with a hinge deletion. Proc. Natl. Acad. Sci. USA. 90, 4271-4275 (1993
9. Harris L.J., Skaletsky E., & McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275, 861-872 (1998
10. Saphire E.O., et al. Crystal structure of a neutralizing human IgG against HIV-1: a template for vaccine design. Science. 293, 1155-1159 (2001
11. Harris L.J., Larson S.B., Hasel K.W., & McPherson A. Refined structure of an intact IgG2a monoclonal antibody. Biochemistry. 36, 1581-1597 (1997
12. Davies A.M., et al. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 426, 630-644 (2014
13. Radaev S., & Sun P. Recognitions of immunoglobulins by Fc? receptors. Mol. Immunol. 38, 1073-1083 (2002
14. Bruhns P., et al. Specificity and affinity of human Fc? receptors and their polymorphic variants for human IgG subclasses. Blood. 113, 3716-3725 (2009
15. Schneider S., & Zacharias M. Atomic resolution model of the antibody Fc interaction with the complement C1q component. Mol. Immunol. 51, 66-72 (2012
16. Pervushin K.V., Wider G., & Wüthrich K. Single transition-To-single transition polarization transfer (ST2-PT) in [15N,1H]-TROSY. J. Biomol. NMR. 12, 345-348 (1998
17. Arbogast L.W., Brinson R.G., & Marino J.P. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance. Anal. Chem. 87, 3556-3561 (2015
18. Tian X., et al. In-depth analysis of subclass-specific conformational preferences of IgG antibodies. IUCrJ. 2, 9-18 (2015
19. Angal S., et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30, 105-108 (1993
20. Richardson J.S. The anatomy and taxonomy of protein structures. Adv. Protein Chem. 34, 167-339 (1981
21. Poppe L., et al. Profiling formulated monoclonal antibodies by 1H NMR spectroscopy. Anal. Chem. 85, 9623-9629 (2013
22. Rayner L.E., et al. The Fab conformations in the solution structure of human immunoglobulin G4 (IgG4) restrict access to its Fc region: implications for functional activity. J. Biol. Chem. 289, 20740-20756 (2014
23. Shields R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276, 6591-6604 (2001
24. Sondermann P., Huber R., Oosthuizen V., & Jacob U. The 3.2-? crystal structure of the human IgG1 Fc fragment-Fc?RIII complex. Nature. 406, 267-273 (2000
25. Hamilton R.G. The Human IgG Subclasses (Calbiochem, 2001
26. Tao M.H., Smith R.I., & Morrison S.L. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J. Exp. Med. 178, 661-667 (1993
27. Oganesyan V., et al. Structural insights into neonatal Fc receptor-based recycling mechanisms. J. Biol. Chem. 289, 7812-7824 (2014
28. Martin W.L., West A.P., Gan L., & Bjorkman P.J. Crystal structure at 2.8 Å of an FcRn/hetrodimeric Fc complex: mechanism of pH-dependent binding. Mol. Cell. 7, 867-877 (2001
29. West A.P., & Bjorkman P.J. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry. 39, 9698-9708 (2000
30. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., & Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 25, 21-50 (2007
31. Quast I., & Lünemann J.D. Fc glycan-modulated immunoglobulin G effector functions. J. Clin. Immunol. 34, S51-S55 (2014
32. Lux A., & Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv. Exp. Med. Biol. 780, 113-124 (2011
33. Barb A.W., & Prestegard J.H. NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nat. Chem. Biol. 7, 147-153 (2011
34. Yang X., et al. Comprehensive analysis of the therapeutic IgG4 antibody pembrolizumab: hinge modification blocks half molecule exchange in vitro and in vivo. J. Pharm. Sci. doi:10.1002/jps.24620 (26 August 2015
35. Vonrhein C., et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 (2011
36. McCoy A.J., et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007
37. Collaborative Computational Project N4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994
38. Murshudov G.N., Vagin A.A., & Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997
39. Emsley P., Lohkamp B., Scott W., & Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010
40. Winn M.D., Isupov M.N., & Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122-133 (2001